Key facts
- Gilgamesh Pharma’s last known valuation is $188.5M (May 2022).
- It has raised $135.8M across 3 recorded rounds; the latest was Seed Round ($2.3M) in Mar 2026.
- Notable investors include Y Combinator, Alumni Ventures, Pioneer Fund, Offline Ventures, What If Ventures — 24 tracked in total.
- 1 investment vehicle was formed to buy Gilgamesh Pharma shares in the last 12 months, reporting $1.8M sold to 25 investors, per SEC Form D filings.
- Gilgamesh Pharma has filed 2 Form Ds with the SEC, most recently Mar 2026 ($2.3M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Gilgamesh Pharma
Funding rounds
3 roundsSecondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Gilgamesh Pharma shares, reporting $1.8M sold to 25 investors. Most recent filing Mar 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Gilgamesh Pharma
Developer of novel chemical entities designed to transform the treatment of psychiatric disorders through rapid-acting and durable therapies. The company offers AI-powered drug discovery capabilities, advanced medicinal chemistry expertise, and orally bioavailable neuroactive compounds with improved safety profiles, enabling patients with depression, anxiety, and substance use disorders to achieve faster relief and sustained therapeutic effects.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 15
- Website
- gilgameshpharmaceutical.com/
- Ownership
- Privately Held (backing)
Gilgamesh Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gilgamesh Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gilgamesh Pharma in its N-PORT filings yet. We sweep new filings monthly.